Oncology biopharmaceutical company Parabilis Medicines has announced the successful closing of a $305 million Series F financing.  The round was co-led by RA Capital Management, Fidelity Management & Research Company and Janus Henderson Investors, with participation from new investors including Frazier Life Sciences, Soleus Capital, and a life science-dedicated investment fund.  The company says the […]